Social media

In the latest issue of Journal for Clinical Studies, Dr. Divya S. Mishra outlines the critical components for successful implementation of radiopharmaceutical programs, including: - Specialised infrastructure and isotope...

In the latest issue of Journal for Clinical Studies, Dr. Divya S Mishra outlines the critical components for successful implementation of radiopharmaceutical programs, including: - Specialised infrastructure and isotope ...

Analysts, rejoice. Metys® offers predefined dashboards for quick answers and a powerful report builder for custom views – plus Excel integration for seamless workflows. It’s market intelligence, your way. Explore Mety...

Analysts, rejoice. Metys® offers predefined dashboards for quick answers and a powerful report builder for custom views – plus Excel integration for seamless workflows. It’s market intelligence, your way. Explore Mety...

ICON is a proud supporter of World Children’s Day which takes place on 20 November. Learn how clinical development for pediatric trials differs from adult trials, with a focus on the unique challenges, critical success f...

How do you choose the right control group for organ impairment trials? Despite consensus on the need for demographic similarity between test and control groups, practical guidance is surprisingly scarce. Too often, sele...

The number of clinical trials using digital endpoints has doubled every 3 years since 2015. The industry is seeing that leveraging DHTs in trials offers: - Faster data collection - Greater sensitivity to treatment effec...

Risk-based strategies aren’t optional, they’re essential. ICON’s Victoria DeVeaugh-Geiss shares six principles sponsors should consider building into their clinical trial operations. Read the blog https://ow.ly/i5kG50Xok...

Did you know LinkedIn has a feature that allows you to privately express your interest in working with ICON? By clicking the 'I'm interested' button on our company page, you can signal to our Talent Acquisition team tha...

Regulators, patients, and sponsors are all asking: Does this treatment improve life beyond the numbers? And in obesity trials, the number on the scale is only a portion of what patients care about. Learn more about wh...

By 2050, the number of people living with diabetes is projected to rise to 853 million. In the past 5 years, ICON has conducted 198 metabolic studies involving 50,000+ patients and healthy volunteers at 8,600+ sites, inc...

This World Diabetes Day, the theme ‘Diabetes and the workplace’ reminds us that 70% of people living with diabetes are of working age. At ICON, we recognise the urgency of advancing therapies that improve outcomes for t...